Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (251-260 of 290) with videos related to

Pageof 29
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2022
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup AnalysisKazutaka Sunami, Takashi Ikeda, Shang-Yi Huang, et al.
British Journal of Haematology|July 28, 2021
A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survivalTakeshi Yamashita, Hiroyuki Takamatsu, Koji Kawamura, et al.
International Journal of Hematology|March 6, 2009
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemiaHisashi Sakamaki, Ken-Ichi Ishizawa, Masafumi Taniwaki, et al.
Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.
Haematologica|July 20, 2023
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugsHiroyuki Takamatsu, Tomohiro Matsuda, Shohei Mizuno, et al.
British Journal of Haematology|October 11, 2021
Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumabKisato Nosaka, Shigeru Kusumoto, Nobuaki Nakano, et al.
Japanese Journal of Clinical Oncology|May 7, 2021
Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)Nobuhiko Nakamura, Dai Maruyama, Ryunosuke Machida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.
Annals of Hematology|September 11, 2023
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in JapanYuichi Horigome, Masaki Iino, Yoriko Harazaki, et al.
British Journal of Haematology|May 10, 2020
Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohortTakashi Kanamori, Masashi Sanada, Masaki Ri, et al.
Pageof 29

Showing results (251-260 of 290) with videos related to

Sort By:
Pageof 29
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2022
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup AnalysisKazutaka Sunami, Takashi Ikeda, Shang-Yi Huang, et al.
British Journal of Haematology|July 28, 2021
A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survivalTakeshi Yamashita, Hiroyuki Takamatsu, Koji Kawamura, et al.
International Journal of Hematology|March 6, 2009
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemiaHisashi Sakamaki, Ken-Ichi Ishizawa, Masafumi Taniwaki, et al.
Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.
Haematologica|July 20, 2023
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugsHiroyuki Takamatsu, Tomohiro Matsuda, Shohei Mizuno, et al.
British Journal of Haematology|October 11, 2021
Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumabKisato Nosaka, Shigeru Kusumoto, Nobuaki Nakano, et al.
Japanese Journal of Clinical Oncology|May 7, 2021
Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)Nobuhiko Nakamura, Dai Maruyama, Ryunosuke Machida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.
Annals of Hematology|September 11, 2023
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in JapanYuichi Horigome, Masaki Iino, Yoriko Harazaki, et al.
British Journal of Haematology|May 10, 2020
Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohortTakashi Kanamori, Masashi Sanada, Masaki Ri, et al.
Pageof 29